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Abstract 
 
Herpes zoster (HZ, shingles, zoster) is a disease due to reactivation and multiplication of 
persistent varicella zoster virus (VVZ) after suffering from previous varicella with 
characteristics of dermatomal rashes, pain, and unilateral. Dermatoms most often involved 
in HZ lesions are thoracal, trigeminal, lumbal, and cervical. The first lesion is usually 
erythematous macule or papule, which then turns into vesicle, then to pustule and to 
become crust, and persists for 2-3 weeks. The main goal of antiviral therapy in HZ patients 
is to reduce the expansion, duration, and severity of rashes and pain in primary 
dermatomes; prevent the spread of HZ to other places; and prevent post-herpes neuralgia. 
One of the prevention strategies for HZ in the elderly and high-risk individuals is 
vaccination using the varicella zoster virus vaccine that is live zoster vaccine or 
recombinant zoster vaccine. 
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Introduction 
Herpes zoster (HZ) (shingles, zoster) is a disease with a characteristic rash and 
unilateral dermatomal pain distribution caused by reactivation and multiplication of 
endogenous varicella zoster virus (VZV), persisting in latent phase in sensory ganglia after 
previous episode of varicella.1,2 
 Several classical clinical manifestations include painful herpetiform clustered 
vesicles, with an erythematous base, which is limited in one or two dermatomal areas. HZ 
occuring in healthy, immunocompetent individuals will reach spontaneous resolution and 
disappear without interventions. HZ on children may be of lighter severity compared to 
adults. Patients over 50 years of age and immunocompromised individuals harbor higher 
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risk of acquiring HZ with clinical manifestations of rash, pain, and severe complications, 
causing distress and reducing quality of life.3,4 
 Medications will be the most effective for patients having the risk of bearing long 
and severe symptoms, especially immunocompromised individuals and those over 50 
years of age. In general, drug choices differ by immunity status and personal clinical 
manifestations.3,4 
 One of the preventive strategies of HZ in general population, especially elderly 
and high-risk groups, is to stimulate immunity agains VZV by vaccination.3 
 
Clinical Manifestation 
A few days before rash eruption, fever, malaise, myalgia, headache, pain and paresthesia 
around dermatom occur. Most often, constant or intermittent pain is experienced by those 
older than 60, which varies from superficial tingling or itching, burning, till lancinating 
pain. Onset of pain is 48-72 hours before the first rash appear. Some patients may 
experience zoster sine herpetic with the form of acute segmental neuralgia without skin 
lesions.1,4,6 
 The most common clinical manifestation is unilateral distribution of rash, usually 
limited to one or two dermatoms. The first lesion is usually erythematous macule or 
papule, which then 12-24 hours after turns into vesicle, then to pustule by the third day. 
After 7-10 days, the pustule dries off to become crust, and persists for 2-3 weeks. New 
lesions may appear for the first 1-4 days (sometimes up to 7 days).1 Classical rash appear 
as painful herpetifom grouped vesicles sitting on an erythematous base, and is limited to 
one or two dermatoms.3,6 Skin lesions usually heal without residual rash, but may turn 
into hypo/hyperpigmentation following inflammation or scarring. Skin rash will be more 
severe and longer in older individual; therefore it is less severe and shorter in pediatric 
population.1 Sometimes, reginal lymphadenopathy may occur.3 
 Clinical manifestations can highly vary. HZ most often occurs in dermatoms with 
the most number of varicella lesions.1 Dermatom related to HZ lesion are usually within 
centripetal distribution of the initial varicella lesion. During varicella, virus spreads from 
skin lesion to sensory nerve endings, then ascends to ganglion. Other hypothesis believes 
that the ganglion is infected by hematogen route during viremia phase of varicella, and 
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reactivation stimulus occurs most often in these ganglions.3,6 Dermatoms most often 
involved in HZ lesions are thoracal, trigeminal, lumbal, and cervical.10 
 HZ oticus (geniculate zoster, zoster auris, Ramsay Hunt syndrome, Hunt 
syndrome) occurs with involvement of geniculatum ganglion. The classic appearance is 
otalgia with herpetiform vesicles in external auricular canal or tympanic membrane, with 
or without facial paralysis, auditory symptoms (hearing disturbance), and vestibular 
symptoms. Ramsay Hunt syndrome triad consists of HZ lesion on ear, ipsilateral facial 
palsy, and anesthesia in 2/3 anterior of the tongue. This syndrome is caused by 
involvement of N. VII, IX, and X.3 
 HZ involving the eyelids signifies the involvement of the first branch 
(ophthalmicus) of trigeminal nerve, and is named HZ ophthalmicus. This type is often 
experienced by the elderly. HZ lesions on the bridge of the nose (Hutchinson’s sign) is a 
predictor of ocular involvement. On occasions, blepharoconjunctivitis, keratitis, uveitis, 
and secondary glaucoma may occur.3,6 
 The involvement of second branch (maxillaris) and third branch (mandibularis) of 
trigeminal nerve causes intraoral HZ lesions accompanied with tooth pain. Maxillary 
branch involvement causes lesions in ipsilateral cheek, upper and lower lid, side of nose, 
nose mucose membrane, nasopharyng, tonsils, upper teeth, palatum, uvula, and tonsilar 
fossa. Involvement of mandibular branch causes lesions on the side of the head, external 
ear, external auricular cannal, lower lip, base of mouth, buccal mucose membrane, and 
tongue.3,6 
 Disseminated HZ is a generalized eruption with more than 10-12 extradermatomal 
vesicles, 7-14 days after the onset of classic dermatomal HZ. Disseminated HZ indicate 
decreased cellular immunity with various causes, including malignancy, radiation therapy, 
cancer chemotherapy, organ transplantation, or long term corticosteroid medications.3 In 
the immunocompromised, new lesions may appear till up to 2 weeks, and viremia with 
disseminated rash may occur with complications involving skin necrosis, scar, and 
visceral organ involvement including lungs, liver, and brain. HZ patient with active HIV 
infection may experience recurrent HZ in the same dermatom or other dermatoms. HZ 
patients with AIDS may experience severe HZ with dissemination to the skin and visceral 
organs, including acyclovir-resistant VZV with verrucose or hyperkeratotic lesions.1,8,10 
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 HZ complications don’t happen often in healthy children and adults, and most 
commonly reserved to the immunocompromised. The frequently reported complication is 
post herpetic neuralgia (PHN), which is a persistent pain for more than 4 weeks after HZ 
onset, and occuring 60% in patients >60 years old. Some skin complications include 
secodary bacterial infection, scar, zoster gangrenosum, and cutaneous dissemination. 
Ocular complications include conjunctivitis, keratitis, corneal ulcer, iridocyclitis, 
glaucoma, and blindness. Some visceral complications include pneumonitis, hepatitis, 
esophagitis, gastritis, cystitis, and arthritis. Neurological complications involve 
meningoencephalitis, cranial nerve palsy, sensory loss, deafness, peripheral nerve palsy.1 
 
Diagnosis 
HZ diagnosis is mainly based on anamnesis and physical examinations, with focus 
on the characteristic location and rash appearance with local pain.6 Laboratory diagnosis 
confirmation is done on atypical HZ patients, visceral organ and central nervous system 
involvement, or zoster sine herpete. Some laboratory diagnosis confirmation involve 
Tzanck smear, polymerase chain reaction (PCR), direct immunofluorescence assay 
(DFA), skin biopsy, and culture. 
 Tzanck smear is a simple and affordable laboratory confirmation test, but it cannot 
differentiate VZV with other herpesviruses. PCR may detect VZV DNA in skin lesion 
samples and visceral organs. PCR and VZV IgG test with cerebrospinal fluid sample are 
the first line laboratory examinations on HZ patients with visceral organ and central 
nervous system involvement. Skin biopsy and PCR can assist diagnosis on zoster sine 
herpetic cases.3,6 
 
Treatment 
During acute phase, in order to subside local symptoms and hasten vesicular lesion 
drying, a patient may do a compress with sterile saline solution, Burowi solution, or lotio 
calamin, which is applied on the involved skin for 30-60 minutes, 4-6 times a day. Topical 
antiviral therapy is proven not effective, thus is not recommended.1,3,6,8 
 The main objective of antiviral therapy on HZ patients is to limit spread, duration, 
and severity of lesion and pain on primary dermatom, reduce distribution of HZ to other 
locations, and prevent PHN.1 
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 Most complications are caused by prolonged replication and VZV spread from the 
involved ganglion. Therefore it should be prevented by quick and effective antiviral 
therapy.1 Nucleoside analogues such as acyclovir, famcyclovir, and valacyclovir, and 
pirophosphate analogue phoscarnet has been proven to be effective to treat VZV infection. 
Afterwards, cellular enzymes will transform acyclovir monophosphate to acyclovir 
triphosphate which inhibits DNA polymerase virus to stop virus DNA synthesis.1 
Phoscarnet is an inorganic pirophosphate analogue which inhibits viral replication. 
Antiviral activity is brought forward by selective inhibition on DNA polymerase and 
reverse transcriptase pyrophosphate-binding site, but it doesn’t influence cellular DNA 
polymerase. Phoscarnet antiviral activity doesn’t require phosphorilation by timidine 
kinase, thus proven effective for acyclovir-resistant VZV.1,8 
 
Herpes Zoster on Immunocompetent Adolescents and Adults 
  Antiviral therapy is recommended to reduce time of lesion healing, duration and 
severity of acute pain on adult patient. Medication is administered in ≤72 hours after rash 
onset. Antiviral therapy is recommended, even for those with lesion onset of >72 hours, 
if new vesicles still emerge, any cutaneous lesions exist, disseminated visceral or 
neurological involvement is suspected, HZ subtype is opthalmicus or oticus, and all 
immunocompromised patients.1,3,9,11 
 Antiviral drug regimen recommended for immunocompetend adolescents and 
adults are:1 
- Those <50 years old: symptomatic therapy; or oral famcyclovir 3dd 500 mg for 7 
days; or oral valacyclovir 3x1 gram for 7 days; or oral acyclovir 5x800 mg for 7 
days. 
- Those ≥50 years old, and any age with cranial nerve involvement (for example, 
HZ ophthalmicus): oral famcyclovir 3x500 mg for 7 days; or oral valacyclovir 3x1 
gram for 7 days, or oral acyclovir 5x800 mg for 7 days. 
 
The choice of drug depends on the price of the medicine and frequency of dosages 
in a day. Famcyclovir and valacyclovir are prefered compared to acyclovir for oral therapy 
due to their pharmacological advantages, less frequency of administration in a day, and 
higher antiviral activity in the bloodstream.1,3,12 
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 Ophthalmicus HZ is better treated alongside ophthalmologists to prevent ocular 
complications, especially when the eye is involved.8,9 
 
Herpes Zoster on Immunocompromised Patients 
Less severe HZ on immunocompromised patients or those with local HZ may be given 
oral acyclovir, famcyclovir, or valacyclovir.1,3,9 Treatment regimen for 
immunocompromised individuals involve:1 
- Mild immunocompromise, involving HIV infection: oral famcyclovir 3x500 mg 
for 7-10 days; or oral valacyclovir 3x1 gram for 7-10 days; or oral acyclovir 5x800 
mg 7-10 days. 
- Severe immunocompromise: intravenous acyclovir 10 mg/kg, 3x daily for 7-10 
days. 
- Acyclovir-resistant (AIDS end stage): intravenous phoscarnet 40 mg/kg 3x daily 
till resolution. 
Herpes Zoster on Pregnant Women and Children 
Pregnant women with HZ should be considered to be treated as soon as possible, 
to hasten lesion healing and reduce intensity and length of pain period. The recommended 
antiviral therapy for pregnant women are oral acyclovir 5x800 mg/day for 7-10 days and 
oral valacyclovir 3x100 mg/day for 7 days.4,13,14 Famcyclovir isn’t recommended for 
pregnant and breastfeeding women.14 Intravenous acyclovir therapy is given to pregnant 
women with HZ involving cranial nerves, ocular nerve, mucose membrane, hemorrhagic 
lesion, disseminated lesion, and pneumonitis. Intravenous dosage ranges from 10-15 
mg/kg, or 500 mg/m2 every 8 hours, for 5-10 days.13,14 
 Herpes zoster doesn’t occur often in children, and if it does, it is majorly mild. 
Antiviral therapy is recommended if complications are present, if they are 
immunocompromised, or new lesions keep emerging after 3 weeks course of disease. 
Acyclovir is given orally, with dosage 20 mg/kg/dosage (maximum of 800 mg/dosage), 5 
times per day, for 5-7 days. For immunocompromised children with severe HZ, they are 
given intravenous acyclovir 10 mg/kg or 500 mg/m2 every 8 jam, for 7-10 days.4,9,15 
 
Anti-inflammatory Therapy 
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Corticosteroid usage for HZ is still debated. Inflammation happening in sensory 
ganglia plays a role in PHN, thus for its prevention, one may be given corticosteroid 
during acute phase of HZ. Initiation of corticosteroid must be hand-in-hand with antiviral 
therapy.1,4,10,16 The duration of corticosteroid treatment should not exceed antiviral 
therapy.1 Combination of acyclovir and corticosteroid is recommended for healthy adult 
HZ patients with moderate – severe pain, if neurological symptoms are significant, or if 
central nervous system, Ramsay-Hunt syndrome, or ocular complications are 
involved.3,4,9,10 
 The studies about acyclovir and corticosteroid combination therapy reported 
various dosage, route of administration, and treatment period. Dworkin reported prednison 
usage at 60 mg/day for 1 week, then tappered off to 30 mg/day for 1 week, followed by 
15 mg/day for 1 week.10,11 Murakami reported Ramsay-Hunt syndrome medication using 
acyclovir 250 mg IV 3 times daily, or oral acyclovir 5x800 mg/day for 7 days, combined 
with intravenous or oral prednison 1 mg/kg/day with two divided doses for 5 days, 
tappered off slowly and stopped in 10 days. Coulson reported treatment of Ramsay-Hunt 
syndrome using oral acyclovir 5x200 mg/day for 21 days, followed with oral prednison 1 
mg/kg/day for 14 days then tappered off to 10 mg/day before stopped.4 
 
Treatment of Acute Pain in HZ 
Most of HZ patients experience acute pain, and it is usually the most reported 
symptom. Analgetics are necessary as adjuvants to antiviral therapy.9 Choice and dosage 
of drug depends on pain severity, underlying diseases, and response to medication.1,9 
Patients with HZ and mild pain may be given oral acetaminophen for 325-1000 mg 4-6 
times per day, or nonsteroidal anti-inflammatory drugs (NSAIDs) like oral ibuprofen 400 
mg 4- times daily. Acetaminophen and NSAIDs are the drugs of choice to control HZ 
acute pain.10,11,17 Healthy HZ patient reporting moderate – severe acute pain on 
presentation, or with risk factors for PHN (women, age over 50 years od, lesion count 
>50, location in cranial/sacral area, hemorrhagic lesion, or dermatomal pain during 
prodromal phase) are recommended to be given tricyclic antidepressant analgetic, 
anticonvulsant or opiod/non-opioid.9 If pain control is still inadequate, doctors may 
consider to administer nerve block or local anesthesia.1 
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 Anticonvulsant medications gabapentin and pregabalin are reported to reduce 50% 
of acute pain in HZ.17 Gabapentin is used with initial dosage 100 – 300 mg before night 
sleep, and can be increased by 100 – 300 mg, 3 times daily until 3-7 days and pain is 
tolerable (maximum dosage of 3600 mg/day). Pregabalin is used with initial dosage 25 – 
75 mg, 1-2 times daily, and can be increased by 75 mg, 2 times daily for 3-7 days until 
pain is tolerable (maximum dosage of 600 mg/day). Side effects range from somnolence, 
dizziness, ataxia, and peripheral edema.1,10,11,16 
 Triclyclic anidepressants (amitriptiline, nortriptiline, and desipramine) can reduce 
44-67% HZ acute pain.1 Initial dosage is 10-25 mg before night sleep, and can be 
increased 10 – 25 mg weekly until pain is tolerable (maximum dosage of 150 mg/day). 
Side effects include somnolence, dry mouth, blurred vision, sedation, orthostatic 
hypotension, constipation, heart arrhythmia, and urinary retention.7,10,16,17 
 Opioid/non-opioid analgetics are reported to be effective to reduce acute HZ pain, 
some of the medications being oxycodone amd tramadol. Oxycodone is used with initial 
dosage of 5 mg every 4 hours, and can be increased 5 mg 4 times daily every week until 
pain is tolerable (maximum of 120 mg/day). Some reported side effects are nausea, 
vomiting, constipation, sedation, cognitive disfunction, bronchospasm, orthostatic 
hypotension, and itching. Tramadol is used with initial dosage of 50 mg, 1-2 times daily, 
and can be increased 50 – 100 mg/day, given in two divided doses until pain is tolerable 
(maximum of 400 mg/day; 300 mg/day for age >75 years old).10,11,16 
 
Prevention of HZ: 
Varicella Zoster Virus Vaccination 
The prevention of HZ aims to avoid reactivation and spread of latent VZV virus. 
One of the preventive strategies of HZ in the general population, especially the elderly 
and high-risk individuals is to stimulate immunity against VZV.3 
 In the year 2006, the US Food and Drug Administration (FDA) and the Centers 
for Disease Control and Prevention (CDC) recommended the higher potency live 
attenuated vaccine VZV (Zostavax®) to prevent HZ on immunocompetent non-pregnant 
population, aged ≥60 years old, including those who have had previous HZ episode. It is 
given in a single subcutaneous dose on the deltoid area.7,18 Protection spans till 3 years. 
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Several contraindications to this medication is those severely immunocompromised, 
pregnant women, and children.3,10,20 
 In the year 2018, CDC recommended immunization on adults using zoster 
vaccine: 
- 2 doses of recombinant zoster vaccine (RZV) (Shingrix®) 2-6 months apart, is 
used for those aged ≥50 years old, regardless of previous HZ episode, or have 
received live zoster vaccine (ZVL) (Zostavax®). 
- 2 doses of RZV, 2-6 months apart for adults having received ZVL, minimal of 2 
months after ZVL. 
- Administration of one of RZV or ZVL for those aged ≥60 years (RZV is 
preferred).3,20 
 
Varicella Zoster Immune Globulin (VZIG) 
The Centers for Disease Control and Prevention (CDC) recommended passive 
immunization using VZIG to prevent or modify clinical manifestation of VZV infection 
on high risk individuals, children, pregnant women, or immunocompromised individuals 
exposed to varicella or herpes zoster. VZIG is given intramuscullarly, with dosage of 125 
U/10 kg (maximum of 625 U; minimum 125 U) or 0,5-1 mg/kg. The best effect is achieved 
if administered as soon as possible from exposure, and at least ≤96 hours after exposure. 
Protection after VZIG lasts for around 3 weeks.3,7,10 
 
Conclusion 
Classic clinical characteristics of HZ are painful herpetiform grouped vesicles, sitting on 
top of an erythematous base, limited to one or two dermatoms. Skin rash is more severe 
and longer in the elderly, but milder and shorter in children. Dermatoms most often 
involved are thoracal, trigeminal, lumbal, and cervical. Clinical manifestations may vary. 
 HZ diagnosis is based on clinical appearance, and laboratory diagnosis 
comfirmation is done on atypical HZ patients. 
HZ treatment is recommended for those with risk of experiencing long and severe 
symptoms, especially immunocompromised populations and those over 50 years old. 
Acyclovir, famcyclovir, valacyclovir, and phoscanet is proven to be effective to treat VZV 
infection. Medication is administered in ≤72 hours after onset of rash. Combination 
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therapy acyclovir and corticosteroid is recommended for acute moderate – severe pain, 
those experiencing significant neurological symptoms or with central nervous system 
manifestation, Ramsay-Hunt syndrome, and ocular complications. 
 Analgetic medications are given as adjuvants to antiviral therapy to treat acute pain 
in HZ. HZ patients with acute mild pain can be given acetaminophen or NSAIDs. HZ 
patients with moderate – severe pain may be given tricyclic antidepressants analgetic, 
anticonvulsant or opiod/non-opioid. 
 One of the strategies of prevention of HZ in the elderly and high-risk individuals 
is to vaccinate using zoster vaccine live or recombinant zoster vaccine. Passive 
immunization using VZIG is recommended to prevent or modify clinical manifestation of 
VZV infection on high-risk individuals, children, pregnant women, or 
immunocompromised exposed to varicella and herpes zoster. 
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